- Home
- NTIP vs LGVN Comparison
NTIP vs LGVN Comparison
Compare NTIP & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | LGVN |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 21.4M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTIP | LGVN |
|---|---|---|
| Price | $1.58 | $6.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 15.6K | ★ 469.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | 15.38 | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.24 | $0.48 |
| 52 Week High | $1.75 | $7.30 |
Technical Indicators
Market Signals| Indicator | NTIP | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 86.91 |
| Support Level | $1.46 | $0.61 |
| Resistance Level | $1.66 | $7.30 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.00 | 0.36 |
| Stochastic Oscillator | 68.75 | 90.24 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.